EUVIMEDEUVIMED entdecken
Crossref

Ethnic divergence in human leukocyte antigen-linked immunogenicity in inflammatory bowel disease

Taly Issa, Iyad Issa

World Journal of Gastroenterology · 07.07.2026 · 32 (25)

DOI: 10.3748/wjg.115526 ↗

Kurz gefasst

Fachartikel in der Zeitschrift World Journal of Gastroenterology, online erschienen am 07.07.2026. Verfasst von Taly Issa und 1 weiteren Autor:innen. Die Arbeit nennt 60 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Inflammatory bowel disease (IBD), encompassing both Crohn’s disease and ulcerative colitis, poses significant treatment challenges due to its complex etiology and variable therapeutic responses. Anti-tumor necrosis factor biologic therapies have substantially reduced corticosteroid dependence, hospitalization rates, and the need for surgery in moderate-to-severe IBD, yet their clinical utility is frequently compromised by the development of anti-drug antibodies (ADAs) which reduce drug trough levels, diminish therapeutic response, and accelerate treatment failure. Concomitant immunomodulator co-therapy attenuates ADA formation by approximately 47%, but introduces competing risks that necessitate individualized benefit-risk assessment. While the genetic determinants of immunogenicity have been characterized extensively in European populations – most notably the human leukocyte antigen (HLA)-DQA1*05 allele – a clinically consequential gap persists in non-European ethnic groups. This opinion review critically evaluates the work, which identified HLA class I alleles HLA-C*03:04:01 and HLA-B*15:18:01 as ethnic-specific predictors of ADA formation in Taiwanese IBD patients, challenging the presumed universality of HLA-DQA1*05. We place these findings within the broader context of a shifting global IBD epidemiological burden, newly refined four-digit allele subtype evidence in European and East Asian populations, the mechanistic basis of HLA class I-driven immunogenicity, the complementary roles of immunomodulator co-therapy and therapeutic drug monitoring, and the broader precision pharmacogenomics agenda in IBD. We propose that pre-treatment ethnically calibrated HLA-based stratification, integrated with therapeutic drug monitoring-guided monitoring, represents the next frontier in biologic optimization and immunologic safety in IBD.

Zitieren

APA

Issa, T., & Issa, I. (2026). Ethnic divergence in human leukocyte antigen-linked immunogenicity in inflammatory bowel disease. World Journal of Gastroenterology, 32(25). https://doi.org/10.3748/wjg.115526

Vancouver

Issa T, Issa I. Ethnic divergence in human leukocyte antigen-linked immunogenicity in inflammatory bowel disease. World Journal of Gastroenterology. 2026;32(25). doi:10.3748/wjg.115526

BibTeX
@article{Issa2026,
  author = {Issa, Taly and Issa, Iyad},
  title = {Ethnic divergence in human leukocyte antigen-linked immunogenicity in inflammatory bowel disease},
  journal = {World Journal of Gastroenterology},
  year = {2026},
  volume = {32},
  number = {25},
  doi = {10.3748/wjg.115526}
}
Kostenlos starten →